Hormonal
Muscle disuse induces muscle-specific insulin resistance (IR), which accelerates muscle mass loss, particularly in individuals with pre-existing Type 2 Diabetes.
If you have Type 2 Diabetes or insulin resistance, your muscles are more vulnerable to loss during periods of inactivity. Disuse makes your muscles resistant to insulin, which accelerates muscle breakdown. Managing blood sugar and attempting any safe movement or protein intake can help mitigate this accelerated loss.
Immobilization also induces muscle insulin resistance (IR). Moreover, the trajectory of muscle atrophy appears to be accelerated in persistent IR states (e.g., Type II diabetes), suggesting IR may contribute to muscle disuse atrophy under these conditions.
Why this rating
Strong observational data linking IR to accelerated atrophy in diabetes; mechanistic links in simple disuse are less defined but supported by molecular markers.
Source
Human Skeletal Muscle Disuse Atrophy: Effects on Muscle Protein Synthesis, Breakdown, and Insulin Resistance—A Qualitative Review
Supreeth Rudrappa et al. · Frontiers in Physiology · 2016
DOI 10.3389/fphys.2016.00361
More from this paper
- Skeletal muscle disuse (immobilization, bed rest, or unloading) causes rapid muscle atrophy primarily through a significant reduction in muscle protein synthesis (MPS), while muscle protein breakdown (MPB) remains largely unchanged or is not the primary driver.Good
- Disuse atrophy exhibits fiber-type specificity, with Type I (slow-twitch) fibers atrophying faster and to a greater degree than Type II (fast-twitch) fibers during prolonged disuse.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →